Several antibodies against PD-1 (pembrolizumab, nivolumab) and PD-L1 (atezolizumab, durvalumab, avelumab) have already gained approval by the Food and Drug Administration (FDA) for various tumor entities. This evidence concerns the gene PDCD1 and neoplasm.